Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP) (3)
This functional assay was developed for detection of compounds inhibiting Vero E6 cells viability as a secondary screen to the PFM17LAP screen. ..more
BioActive Compounds: 30
Depositor Specified Assays
Southern Research Specialized Biocontainment Screening Center (SRSBSC)
Assay Provider: Donald Gardiner
Award: 1 R03 MH082342-01A1
This functional assay was developed for detection of compounds inhibiting Vero E6 cells viability as a secondary screen to the PFM17LAP screen.
In this assay, we treated Vero E6 cells with compounds selected as hits in the PFM17LAP assay for 72 hours over a 10 point 2-fold dilution series, ranging from 0.19uM to 100 uM. Following 72 hours of treatment, relative viable cell number was determined using Cell Titer Glo from Promega. Each plate contained 64 replicates of vehicle treated cells which served as negative controls.
Cell Culture: Vero E6 cells were subcultured every 7 days in E-MEM with 10% fetal bovine serum and 2 mM glutamine (complete growth medium), incubated at 37 degrees C in 5% carbon dioxide, and maintained for no more than 20 passages.
Compound Dosing/Plating: Carrier control / compounds were diluted in complete growth medium to prepare a 6X concentrated dosing solution which was dispensed into 384-well black clear-bottom tissue culture treated plates (5 uL volume).
Cell Plating: Twenty uL of complete growth medium containing 3000 cells were dispensed per well. Plates were incubated at 37 C, 5% CO2 for 72h prior to endpoint detection.
Endpoint/Detection: At the end of the treatment period, assay plates were removed from the incubator and equilibrated to room temperature for 10 min. Twenty-five uL of Cell Titer Glo reagent was added and plates were incubated for an additional 10 min in the dark. At the end of the incubation, assay plates were analyzed using a PerkinElmer Envision microplate reader in luminescence mode with an integration time of 0.1 s.
Data Analysis: Sixty-four control wells containing cells treated with DMSO vehicle and were included on each assay plate. Compound data was normalized and reported as % viability which was calculated using the following formula: % viability = 100*(Cmpd Lum-Med background)/(Med Cell Ctrl - Med background). The normalized % viability was plotted against the tested concentrations. The CC50 values were calculated using XLfit formula 205, a 4 parameter Levenburg-Marquardt algorithm with maximum and minimum limits set at 100 and 0, respectively and allowing extrapolation to identify weakly active compounds.
Outcome: Compounds that showed <80% cell viability for at least one concentration were defined as "Active" (toxic). If the % viability at all doses was <80%, the compound was defined as "Inactive" (non-toxic). Instances where replicate data sets conflicted on this criteria are listed as "Inconclusive".
The following tiered system has been implemented at Southern Research Institute for use with the PubChem Score: Compounds in the primary screen are scored on a scale of 0-40 based on % activity; a score of 40 corresponds to 100% activity. In the confirmatory dose response screen of primary screen hits, active compounds are scored on a scale of 41-80 based on CC50 result while compounds where activity was not confirmed are given the score 0. Confirmatory dose response and secondary screens of purified and/or resynthesized compounds, indicating the highest degree of confidence) are scored on a scale of 81-100 based on CC50 result. Inactive compounds are given the score 0.
Phenotypic Screen: Yes
Screening Concentration Range Max: 50
Screening Concentration Range Min: 0.098
Assay Format: Cell-based
Assay Type: Viability/Toxicity
Assay Method: End-point
Assay Detection: Bio-luminescence
Used for Hit Validation?: Yes
Used during SAR?: Yes
Secondary Assay Sub-type: Counter-screen Assay
* Activity Concentration. ** Test Concentration.
Data Table (Concise)